Publications
Detailed Information
Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Se Ik | - |
dc.contributor.author | Hwang, Woo Yeon | - |
dc.contributor.author | Lee, Maria | - |
dc.contributor.author | Kim, Hee Seung | - |
dc.contributor.author | Kim, Kidong | - |
dc.contributor.author | Chung, Hyun Hoon | - |
dc.contributor.author | No, Jae Hong | - |
dc.contributor.author | Kim, Jae-Weon | - |
dc.contributor.author | Kim, Yong Beom | - |
dc.contributor.author | Park, Noh Hyun | - |
dc.contributor.author | Song, Yong-Sang | - |
dc.contributor.author | Suh, Dong Hoon | - |
dc.date.accessioned | 2021-02-23T04:43:22Z | - |
dc.date.available | 2021-02-23T13:48:49Z | - |
dc.date.issued | 2020-12-07 | - |
dc.identifier.citation | BMC Cancer. 2020 Dec 07;20(1):1199 | ko_KR |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.uri | https://hdl.handle.net/10371/173375 | - |
dc.description.abstract | Background
To determine if extended chemotherapy improves survival outcomes in patients with platinum-sensitive relapsed epithelial ovarian cancer (EOC) who have residual disease after six cycles of second-line chemotherapy. Methods In this study, 135 EOC patients who experienced platinum-sensitive recurrence after primary treatment between 2008 and 2018, and had a residual tumor ≥0.5 cm (detected on CT scans) after completing six cycles of second-line, platinum-based chemotherapy, were retrospectively reviewed. Based on the number of main therapy cycles (second-line chemotherapy), we divided patients into an extended group (>6 cycles, n = 52) or a standard group (6 cycles, n = 83) and compared patient characteristics and survival outcomes between these groups. Results The extended group had a shorter platinum-free interval after primary treatment than the standard group (median, 11.0 vs. 13.1 months; P = 0.018). Secondary debulking surgery was less frequently performed in the standard group (1.9% vs. 19.3%; P = 0.003). After six chemotherapy cycles, the extended and standard groups showed similar serum CA-125 levels (P = 0.122) and residual tumor sizes (P = 0.232). There was no difference in overall survival (OS) between the groups (P = 0.382), although the extended group had significantly worse progression-free survival (PFS) than the standard group (median, 13.9 vs. 15.1 months; P = 0.012). Multivariate analyses revealed that platinum-free interval was an independent prognostic factor for PFS and OS, but extended chemotherapy was not (PFS: HR, 1.25; 95% CI, 0.84–1.85; P = 0.279; and OS: HR, 1.36; 95% CI, 0.72–2.56; P = 0.342). We observed consistent results in the subset of patients who did not undergo secondary debulking surgery. Conclusions More than six cycles of platinum-based chemotherapy might not improve survival outcomes in patients with platinum-sensitive recurrent EOC who had a residual tumor ≥0.5 cm after six cycles of second-line chemotherapy. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.subject | Ovarian cancer | - |
dc.subject | Chemotherapy | - |
dc.subject | Extended | - |
dc.subject | Survival outcome | - |
dc.subject | Recurrence | - |
dc.title | Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김세익 | - |
dc.contributor.AlternativeAuthor | 황우연 | - |
dc.contributor.AlternativeAuthor | 이마리아 | - |
dc.contributor.AlternativeAuthor | 김희승 | - |
dc.contributor.AlternativeAuthor | 김기동 | - |
dc.contributor.AlternativeAuthor | 정현훈 | - |
dc.contributor.AlternativeAuthor | 노재홍 | - |
dc.contributor.AlternativeAuthor | 김재원 | - |
dc.contributor.AlternativeAuthor | 김용범 | - |
dc.contributor.AlternativeAuthor | 박노현 | - |
dc.contributor.AlternativeAuthor | 송용상 | - |
dc.contributor.AlternativeAuthor | 서동훈 | - |
dc.identifier.doi | 10.1186/s12885-020-07658-8 | - |
dc.citation.journaltitle | BMC Cancer | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2021-01-27T09:25:19Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 1199 | ko_KR |
dc.citation.volume | 20 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.